Abbott to split into two companies; GSK plans workforce cuts in Canada;

> Abbott ($ABT) says it plans to separate into two publicly traded companies, one in medical products and the other in research-based pharmaceuticals. Release

> GlaxoSmithKline ($GSK) will cut 9% of its workforce in Quebec City, Canada, primarily from a vaccine manufacturing plant. Story

Pharma IQ has come up with a neat graphic of worldwide serialization and traceability mandates. Infographic

> Kenya is scrambling to retrieve thousands of batches of counterfeit anti-retrovirals following reports of irregularities in the appearance and texture of the drugs. Story

> Sentry BioPharma Services in Indianapolis has signed a 5-year contract with the General Service Administration for inclusion on the federal supply schedule, logistics worldwide, for temperature-controlled storage and distribution of vaccines and biopharma products. Release

> Honeywell ($HON) has unveiled Aclar UltRx 6000, a pharmaceutical packaging film that provides a barrier to protect moisture-sensitive medicines in all climates. Item

> Hikma Pharmaceuticals has inaugurated the Al Dar Al Arabia Pharmaceutical Manufacturing Company in Algeria. Story

> The National Association of State Controlled Substances Authorities (NASCSA) has received a $200,000 grant from Purdue Pharma for the ongoing operation, expansion and awareness of appropriately-designed state prescription drug monitoring programs. Announcement

> Global Logistic Properties is building a dedicated healthcare distribution center in Hangzhou, China. Release

> Movianto Nederland says it is building a 13,000-square-meter GDP-compliant warehouse in Oss, The Netherlands, for storage of deep frozen pharmaceutical products. News

Suggested Articles

Continuing its expansion efforts, Japan’s Fujifilm will make a major investment in its U.S. gene therapy operation in Texas.

Boehringer Ingelheim is investing $50 million in an animal health plant in Puerto Rico, adding 105 jobs.

Teva will begin producing chemo drug vincristine in the U.S. but has resisted the idea that its withdrawal from the market led to a shortage.